Advertisement
"The Chinese government and medical associations are promoting guidelinespublished by the American Diabetes Association, the World Health Organizationand the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst atDecision Resources. "All guidelines advocate earlier and more-aggressiveinterventions in type 2 diabetes patients. We forecast that the patientpopulation treated with polypharmacy will nearly double between 2007 and2012."
Advertisement
The report also finds that three new type 2 diabetes agents with novelmechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis'sGalvus -- are expected to launch in China by 2012. The combined sales of thesethree agents will surpass $270 million by 2012. However, the high cost of manyantidiabetic therapies, particularly Western-branded drugs, is a major barrierto effective management of type 2 diabetes in China. Patient ability to payfor medications influences physician prescribing habits, particularlyprescription of newer drugs such as the peroxisome proliferator-activatedreceptor (PPAR)-gamma agonists and the insulin analogues, which are notreimbursed or are only partially reimbursed in some provinces.
About Emerging Markets - China
Emerging Markets - China is the first and only syndicated report seriesfocusing on high-growth emerging markets with comprehensive disease-specificanalysis. With these reports, biopharmaceutical companies can accomplish thefollowing:
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader inresearch publications, advisory services, and consulting designed to helpclients shape strategy, allocate resources, and master their chosen markets.Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- More accurately assess the commercial opportunity for Western brands in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou -- and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing, Hangzhou, and Jinan. -- Understand the physician treatment patterns and drivers of choice in key first- and second-tier cities based on primary research. -- Gain a clear perspective of the Chinese five-year market forecast at the drug level, broken out by urban and rural areas, and by sales from multinational and Chinese-based companies.
SOURCE Decision Resources, Inc.
